Mmv
Non-Profit & Charitable Organizations · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Rte De Pré-bois 20, Geneva, Geneva, 1215...Phone Number
+41 225550300Website
www.mmv.orgRevenue
$6.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Mmv
Medicines for Malaria Venture (MMV) is dedicated to developing and delivering innovative antimalarial medicines aimed at saving lives and combating malaria. The organization focuses on creating tailored treatments for vulnerable populations, including children and pregnant women, while addressing issues like drug resistance. MMV promotes equitable partnerships and local ownership in research and development processes to enhance clinical trial capacity and strengthen local health infrastructures. With a commitment to achieving a malaria-free world, MMV continues to innovate and work towards the global goal of zero malaria deaths.Explore more
Mmv Org Chart
TT
General Manager, Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mmv your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Mmv, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Mmv recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Mmv
Funding: Get notified immidiatlly once Mmv has new funding data
Click to see if Mmv had a recent Job posting/layoffs
Check out if Mmv is spiking on competitors!
Product Launch: Get notified when Mmv launches new products
Check if Mmv has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Mmv
Find more new buyers
Company Profile Activity
Activity Insights
Mmv is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Mmv is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Mmv.
Mmv Tech Stack
A closer look at the technologies used by Mmv
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Person-Based
Mmv News & Media
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines for Malaria Venture (MMV).Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
TOKYO, April 21, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2...Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Basel, November 12, 2025 – Novartis today announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). The novel non-artemisinin antimalarial, which was developed with Medicines for Malaria Venture (MMV), met the study’s primary endpoint of non-inferiority to the current standard of care. The treatment achieved a 97.4% PCR-corrected cure rate using an estimand framework, compared to 94.0% with standard of care. This equates toEyam Health strikes partnership with Swiss non-profit to develop one-dollar malaria treatment
Eyam claims its AI drug discovery and delivery platform can develop treatment at less than half the usual cost. The post Eyam Health strikes partnership with Swiss non-profit to develop one-dollar malaria treatment first appeared on BetaKit.
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mmv
Sign Up For FreeTo access detailed company insights
Medicines for Malaria Venture (MMV) is dedicated to developing and delivering innovative antimalarial medicines aimed at saving lives and combating malaria. The organization focuses on creating tailored treatments for vulnerable populations, including children and pregnant women, while addressing issues like drug resistance. MMV promotes equitable... Read More
